|
FY2025
12 months to Jan 31, 2025
|
FY2024
12 months to Jan 31, 2024
|
FY2023
12 months to Jan 31, 2023
|
FY2022
12 months to Jan 31, 2022
|
|
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net loss | ||||
| Adjustments to reconcile net loss to net cash used in operating activities | ||||
| Depreciation and amortization | ||||
| Amortization of debt issuance costs | ||||
| Debt prepayment costs | ||||
| Stock-based compensation, net of amounts capitalized | ||||
| Amortization of deferred commissions | ||||
| Non-cash lease expense | ||||
| Net accretion of discounts on short-term investments | ||||
| Impairment of capitalized internal-use software | ||||
| Foreign currency transaction losses | ||||
| Other | ||||
| Changes in operating assets and liabilities: | ||||
| Accounts receivable | ||||
| Deferred commissions | ||||
| Prepaid expenses and other assets | ||||
| Accounts payable | ||||
| Accrued compensation and benefits | ||||
| Other accrued expenses | ||||
| Operating lease liabilities | ||||
| Deferred revenue | ||||
| Net cash used in operating activities | ||||
| Cash flows from investing activities: | ||||
| Purchases of short-term investments | ||||
| Maturities of short-term investments | ||||
| Additions to property and equipment | ||||
| Net cash (used in) provided by investing activities | ||||
| Cash flows from financing activities: | ||||
| Payments of debt | ||||
| Proceeds from issuance of debt, net of issuance costs | ||||
| Proceeds from issuance of Series G redeemable convertible preferred stock, net of issuance costs | ||||
| Proceeds from exercise of stock options | ||||
| Proceeds from issuance of common stock under ESPP | ||||
| Proceeds from initial public offering, net of underwriting discounts and commissions | ||||
| Payment for fractional shares in reverse stock split | ||||
| Payments of deferred offering costs | ||||
| Net cash provided by financing activities | ||||
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | ||||
| Net (decrease) increase in cash, cash equivalents and restricted cash | ||||
| Cash, cash equivalents and restricted cash: | ||||
| Beginning of period | ||||
| End of period | ||||
| Cash and cash equivalents | ||||
| Restricted cash included in other assets | ||||
| Total cash, cash equivalents and restricted cash | ||||
| Supplemental disclosures of cash activities: | ||||
| Cash paid for income taxes | ||||
| Cash paid for interest | ||||
| Non-cash investing and financing activities: | ||||
| Stock-based compensation capitalized as internal-use software costs | ||||
| Net change in unrealized gains or losses on available-for-sale debt securities | ||||
| Change in deferred offering costs included in accounts payable and other accrued liabilities | ||||
| Conversion of redeemable convertible preferred stock to common stock | ||||
| Change in purchases of property and equipment included in accounts payable and other accrued liabilities | ||||
Loading...